Bladder Cancer News and Latest Research
- Cretostimogene reduces NMIBC recurrence risk by 68% in Phase 3 PIVOT-006, company reports Phase 3 RCT · Dealroom · 2026-11-16
CG Oncology announced topline results from its Phase 3 PIVOT-006 trial, reporting that cretostimogene reduced recurrence risk by 68% in NMIBC patients, with no patients discontinuing treatment due to related side effects. Full data and statistical details have not yet been disclosed.
Why it matters: A company-reported Phase 3 topline result suggests cretostimogene may offer a new intravesical option for NMIBC, pending full data disclosure and FDA review.
- Pooled phase 2/3 trials show 78% complete response with UGN-102 in recurrent low-grade NMIBC Retrospective · Urol Oncol · 2026-11-17
A pooled exploratory analysis of four phase 2/3 trials found 78.3% complete response at 3 months with UGN-102 in recurrent low-grade intermediate-risk NMIBC, with 79.7% remaining event-free at 12 months after response in the ATLAS/ENVISION subset. Within the ATLAS trial, UGN-102 showed higher 3-month CR (73.7% vs 51.5%) and higher 12-month event-free probability after CR (68.8% vs 44.2%) than TURBT.
Why it matters: Pooled phase 2/3 data add longer-term efficacy and safety evidence for UGN-102, an FDA-approved nonsurgical option for recurrent low-grade NMIBC.
- Adding trilaciclib to chemo-immunotherapy did not improve PFS in advanced urothelial cancer RCT · Clin Genitourin Cancer · 2026-11-17
In a randomized phase 2 trial of 92 patients with advanced urothelial carcinoma, adding trilaciclib to platinum chemotherapy plus avelumab maintenance showed modest myeloprotective effects but no improvement in progression-free survival (6.6 vs 6.1 months overall, HR 0.94).
Why it matters: Indicates trilaciclib added to standard first-line chemoimmunotherapy does not improve antitumor efficacy in advanced urothelial cancer.
- Continuous antibiotic prophylaxis after cystectomy tied to more resistant organisms, no infection benefit Retrospective · BJU Int · 2026-11-17
In a single-center retrospective cohort of 223 cystectomy patients, continuous oral antibiotic prophylaxis until stent removal showed no reduction in surgical site infection, UTI, or readmission compared to a short stent-removal course, but was linked to more Pseudomonas and other uncovered organism isolation.
Why it matters: Raises the question of whether prolonged antibiotic prophylaxis after cystectomy offers any benefit while potentially increasing resistant organism isolation.
- Biomarker-guided surveillance cuts cystoscopies in NMIBC without clear oncologic harm Meta-analysis · World J Urol · 2026-11-16
A meta-analysis of two randomized trials (DaBlaCa-15 and UroFollow, 606 patients, 590 in primary analyses) found biomarker-guided surveillance reduced cystoscopy use by 55.8% and 74.9% in the two trials respectively, with no significant difference in any recurrence (RR 1.04, 95% CI 0.77-1.41), high-grade recurrence or progression (RR 1.03, 95% CI 0.61-1.74), or progression to muscle-invasive/metastatic disease (RR 0.57, 95% CI 0.12-2.67); non-inferiority was not established.
Why it matters: Offers early randomized support for reducing cystoscopy burden in NMIBC surveillance, but confirmatory data are needed before changing guideline-based follow-up.
- FDA approves durvalumab with enfortumab vedotin for muscle-invasive bladder cancer FDA approval · FDA · 2026-11-13
FDA approved the perioperative combination of durvalumab (an immune checkpoint inhibitor) and enfortumab vedotin-ejfv for muscle-invasive bladder cancer.
Why it matters: Adds a new FDA-approved perioperative regimen option for muscle-invasive bladder cancer.
- Claims data: psychiatric diagnoses common after cystectomy regardless of diversion type Retrospective · Urology · 2026-11-15
In a TriNetX claims analysis of over 13,000 cystectomy patients, neobladder recipients had a transient excess of new mood disorder diagnoses in the first month (RR 1.81) that equalized with ileal conduit patients by 6 months; roughly a quarter of all patients had a new or recurrent psychiatric diagnosis by 5 years.
Why it matters: Hypothesis generating from claims data lacking clinical detail; suggests mental health needs after cystectomy are common and not clearly tied to diversion type long-term.
- Propensity-matched study inconclusive on histologic subtype risk in bladder-preserved NMIBC Retrospective · Clin Genitourin Cancer · 2026-11-15
In a propensity score-matched cohort of 456 NMIBC patients, those with histologic subtypes, divergent differentiation or neuroendocrine components had imprecise progression (HR 1.30, 95% CI 0.36-4.66) and recurrence (HR 0.59, 95% CI 0.27-1.31) estimates versus conventional urothelial carcinoma.
Why it matters: Raises the question of bladder-preserving approaches in variant histology NMIBC but the small event count and wide confidence intervals prevent any practice conclusion.
- FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection FDA action · Urology Times · 2026-11-10
The FDA granted De Novo authorization to the Virtuoso Robotic System, a device intended for robotic resection of bladder tumors.
Why it matters: A new dedicated robotic platform for transurethral bladder tumor resection adds to options for NMIBC management.
- Reconstructed-data analysis: newer BCG-unresponsive NMIBC drugs do not outperform gem/doce Retrospective · Urol Oncol · 2026-11-11
Using reconstructed individual patient data from registration trials, researchers found that none of the FDA-approved BCG-unresponsive NMIBC therapies (nadofaragene, pembrolizumab, nogapendekin alfa inbakicept, TAR-200) showed higher 3-month complete response, durability of response, or disease-free survival than intravesical gemcitabine/docetaxel; gem/doce had higher papillary-cohort DFS than pembrolizumab…
Why it matters: Raises the question of whether gem/doce should remain the benchmark for newer approved agents, though cross-trial, reconstructed-data comparisons limit certainty.
- ANKTIVA plus BCG meets primary endpoint in randomized BCG-naive NMIBC trial RCT · Business Wire · 2026-11-09
The randomized QUILT-2.005 trial of ANKTIVA (nogapendekin alfa inbakicept) added to BCG met its primary endpoint in patients with BCG-naive non-muscle invasive bladder cancer, according to a company announcement; detailed results were not reported.
Why it matters: A positive randomized readout in the BCG-naive setting could expand use of this combination beyond the BCG-unresponsive population already approved.
- Israel approves ANKTIVA plus BCG for BCG-unresponsive NMIBC with CIS Intl regulatory · Business Wire · 2026-11-09
Israel's Ministry of Health approved ANKTIVA (nogapendekin alfa inbakicept) combined with BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.
Why it matters: Adds another regulatory jurisdiction to the approval already in place in the US for this combination.
- Post hoc THOR analysis links durable tumor response to erdafitinib with longer survival Retrospective · BJU Int · 2026-11-10
A post hoc analysis of the THOR trial found that among erdafitinib-treated patients with FGFR-altered metastatic urothelial carcinoma, those with durable objective response had substantially longer 6-month landmark overall survival than those with non-durable response (HR 8.71).
Why it matters: Suggests response durability, not just objective response rate, may better capture clinical benefit with erdafitinib, though this is a non-prespecified secondary analysis.
- LifeBiotic opens randomized trial of oral botanical LCS103 to prevent NMIBC recurrence Trial opening · LifeBiotic (company press release) · 2026-11-05
Startup LifeBiotic has begun enrolling an open-label randomized trial of LCS103, an oral multi-component herbal formulation, given with standard care for non-muscle invasive bladder cancer. About 60 patients at Rambam Health Care Campus will be assigned 1:1 to one year of LCS103 tablets twice daily plus standard care, or standard care alone, stratified by EAU risk group (NCT07728474).
Why it matters: An early look at a botanical approach to NMIBC recurrence; the primary endpoint is safety, with recurrence and quality of life also tracked.
- Preoperative sarcopenia linked to worse survival after radical cystectomy Retrospective · Clin Genitourin Cancer · 2026-11-07
In a single-center cohort of 320 patients, CT-defined sarcopenia (present in 50%) was independently associated with worse overall survival after radical cystectomy (HR 1.52), though not with major complications or ICU use.
Why it matters: Raises the question of whether CT-based muscle mass assessment could help risk-stratify cystectomy candidates, but is hypothesis generating from a single-center retrospective cohort.
- NICE backs perioperative pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer Intl regulatory · pharmaphorum · 2026-11-05
NICE draft guidance recommends pembrolizumab (Keytruda) with enfortumab vedotin (Padcev) before and after cystectomy for muscle-invasive bladder cancer, based on the KEYNOTE-905 and KEYNOTE-B15 trials.
Why it matters: If finalized, NHS patients in England with muscle-invasive bladder cancer gain access to the perioperative regimen.
- Systematic review: BCG-induced granulomatous prostatitis often mimics prostate cancer on MRI Review · World J Urol · 2026-11-06
Across 47 studies, PSA elevation occurred in 54% and PI-RADS 4-5 lesions in 87% of BCG-induced granulomatous prostatitis cases, yet biopsy-confirmed prostate cancer was found in only 7.9%.
Why it matters: Suggests clinicians should consider BCG-induced granulomatous prostatitis in the differential before biopsying suspicious MRI findings in BCG-treated NMIBC patients.
- Postresection urinary tumor DNA sharpens residual disease and recurrence prediction in NMIBC Retrospective · JCO Precis Oncol · 2026-11-06
In 161 NMIBC patients undergoing repeat TURBT, residual tumor was found in 57 (35.4%); adding utDNA to core, expanded, and CIS-augmented indication sets raised AUC for residual tumor detection from 0.544, 0.537, and 0.513 to 0.891, 0.892, and 0.890 respectively, and improved recurrence c-indices from 0.602 to 0.774 (EAU), 0.717 to 0.837 (EORTC), and 0.770 to 0.824 (CUETO).
Why it matters: Suggests utDNA could help refine selection for repeat TURBT and recurrence risk stratification beyond current guideline-based models, pending prospective validation.
Urology clinical trials · Urology podcasts · Urology videos · Meetings · Daily edition archive
Loading today's edition…